VTRS logo

VTRS
Viatris Inc

3,773
Mkt Cap
$17.4B
Volume
7.36M
52W High
$16.47
52W Low
$8.19
PE Ratio
-5.08
VTRS Fundamentals
Price
$15.04
Prev Close
$14.94
Open
$14.95
50D MA
$14.22
Beta
0.80
Avg. Volume
9.42M
EPS (Annual)
-$3.00
P/B
1.18
Rev/Employee
$476,440.00
$27,822.22
Loading...
Loading...
News
all
press releases
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual...
PR Newswire·24h ago
News Placeholder
More News
News Placeholder
Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Zacks·16d ago
News Placeholder
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 PR Newswire PITTSBURGH, April 13, 2026 PITTSBURGH, April...
PR Newswire·19d ago
News Placeholder
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.
Zacks·22d ago
News Placeholder
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.
Zacks·22d ago
News Placeholder
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
Zacks·22d ago
News Placeholder
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting Viatris Announces Multiple Data Presentations at the 2026 American Society...
PR Newswire·22d ago
News Placeholder
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for...
PR Newswire·1mo ago
News Placeholder
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
Zacks·1mo ago
<
1
2
...
>

Latest VTRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.